Sign in

    Richard Miller

    Research Analyst at Cantor Fitzgerald

    Richard Miller is Vice President at Cantor Fitzgerald & Co., leveraging a doctorate from Princeton University to inform his analytical work. He is recognized for his expertise in financial market analysis, though specific companies under his coverage and detailed performance track records are not publicly disclosed. Miller began his tenure at Cantor Fitzgerald before 2025, following completion of his doctoral studies, but information regarding prior professional experience, success rates, or returns generated is not readily available. His credentials include an advanced academic background, and he maintains a senior analyst role at a leading financial services firm.

    Richard Miller's questions to ADMA BIOLOGICS (ADMA) leadership

    Richard Miller's questions to ADMA BIOLOGICS (ADMA) leadership • Q2 2025

    Question

    Richard Miller of Cantor Fitzgerald inquired about current physician utilization trends for Ascentive and sought a technical explanation of the company's new yield enhancement manufacturing process.

    Answer

    CEO Adam Grossman stated that Ascentive utilization trends remain consistent, with new patient starts and switches from standard IG therapies continuing. He explained that the yield enhancement process involves repurifying a previously discarded waste stream containing IgG, using chromatography and filtration, and then blending it back into the main process, resulting in a 20% or greater increase in bulk IG yield.

    Ask Fintool Equity Research AI

    Richard Miller's questions to uniQure (QURE) leadership

    Richard Miller's questions to uniQure (QURE) leadership • Q2 2025

    Question

    Richard Miller, on for Kristen Kluska at Cantor Fitzgerald, asked for details on the natural history comparators used to inform the external control arm and whether to expect ENROL-HD data in the September update.

    Answer

    Chief Medical Officer Walid Abi-Saab explained that after a thorough assessment of various natural history databases, uniQure proposed using the ENROL-HD dataset as the most appropriate comparator, and the FDA agreed with this approach. He confirmed the upcoming September data will feature a comparison of AMT-130 data to an external control arm derived from ENROL-HD using propensity score matching.

    Ask Fintool Equity Research AI

    Richard Miller's questions to PTC THERAPEUTICS (PTCT) leadership

    Richard Miller's questions to PTC THERAPEUTICS (PTCT) leadership • Q3 2024

    Question

    Richard Miller of Cantor Fitzgerald inquired about the timeline for updates following the Huntington's disease Type C meeting and how the FDA might evaluate the STRIDE registry data for the Translarna resubmission.

    Answer

    CEO Matthew Klein responded that the Huntington's meeting is scheduled for December 2024, with updates to follow once clarity is received. For Translarna, he emphasized the strength of the data package, noting Study 41 showed significant benefit and the STRIDE registry provided confirmatory long-term evidence of a 3.5-year delay in loss of ambulation, making it a compelling application regardless of regulatory flexibility.

    Ask Fintool Equity Research AI